Alveus enters obesity treatment space with $160 million Series A funding round. The company plans to use these funds to support a phase II clinical trial. The goal is to fund ongoing or upcoming studies at this stage of treatment development. Alveus will also use some of the capital to move more of its therapeutic "assets" closer to clinical testing. This means that several of their candidate drugs or technologies are expected to move from the preclinical phase to clinical trials. The article does not provide detailed results of the studies or specific mechanisms of action of the prepared therapies.